Navicare Biotech Co., Ltd.

Navicare Biotech Co., Ltd.

TTPEX:8472
59.50
TWD
-5.80
(-8.88%)
-0.65EPS
1.45BMarket Cap

Total Valuation

TWD

As of June 30, 2026, Navicare Biotech Co., Ltd. carries a market capitalization of 1.45B, placing it among publicly traded companies globally. Its enterprise value stands at 1.60B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.45B
Enterprise Value1.60B

Share Statistics

As of June 30, 2026, Navicare Biotech Co., Ltd. has 17.74M shares outstanding.

Shares Outstanding17.74M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 2.86, and the price-to-book ratio stands at 5.60.

PS Ratio2.86
PB Ratio5.60
P/TBV Ratio5.69
P/FCF Ratio-76.21
P/OCF Ratio-79.78

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 3.17 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.60B versus a market cap of 1.45B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales3.17

Financial Position

As of June 30, 2026, Navicare Biotech Co., Ltd. maintains a current ratio of 0.64, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 123.00, indicating elevated leverage, while an interest coverage ratio of -0.79 demonstrates limited ability to service its debt obligations.

Current Ratio0.64
Quick Ratio0.33
Debt / Equity123.00
Debt / EBITDA-50.14
Interest Coverage-0.79

Financial Efficiency

TWD

Over the twelve months ended June 30, 2026, Navicare Biotech Co., Ltd. posted a negative return on equity (ROE) of -4.32, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.12, reflecting losses generated across the asset base. The company generates approximately 2.55M in revenue per employee across its workforce of 198.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 8.76 indicates how many times Navicare Biotech Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-4.32
Return on Assets (ROA)-1.12
Revenue Per Employee2.55M
Employee Count198.00
Inventory Turnover8.76

Taxes

TWD

Over the twelve months ended June 30, 2026, Navicare Biotech Co., Ltd. recorded 10.63M in income tax expense. The company reported a pretax loss of -775,000.00 and -11.41M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax10.63M

Stock Price Statistics

TWD

As of the close on November 17, 2026, Navicare Biotech Co., Ltd.'s stock has declined approximately 20.67% over the past 52 weeks. The 50-day moving average sits at 67.36, while the 200-day moving average is 71.40.

52-Week Price Change-20.67%
50-Day Moving Average67.36
200-Day Moving Average71.40

Income Statement

TWD

Over the twelve months ended June 30, 2026, Navicare Biotech Co., Ltd. generated 505.82M in revenue and converted that into -11.41M in net income, yielding earnings per share of -0.65. EBITDA reached -6.35M, while operating income came in at -20.94M.

Revenue505.82M
Gross Profit184.99M
Operating Income-20.94M
Pretax Income-775,000.00
Net Income-11.41M
EBITDA-6.35M
EBIT-20.09M
Earnings Per Share (EPS)-0.65

Balance Sheet

TWD

As of June 30, 2026, Navicare Biotech Co., Ltd. holds 165.13M in cash and equivalents against 318.39M in total debt, resulting in a net debt position of 247.24M. Total book value stands at 258.85M, with working capital of -180.72M providing operational flexibility.

Cash & Cash Equivalents165.13M
Total Debt318.39M
Net Debt247.24M
Equity (Book Value)258.85M
Book Value Per Share14.59
Working Capital-180.72M

Cash Flow

TWD

Navicare Biotech Co., Ltd. produced -18.11M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -850,000.00 in capital expenditures, free cash flow totaled -18.96M - equivalent to -1.07 per share.

Operating Cash Flow-18.11M
Capital Expenditures-850,000.00
Free Cash Flow-18.96M
FCF Per Share-1.07

Margins

Over the twelve months ended June 30, 2026, Navicare Biotech Co., Ltd. posted a gross margin of 36.57, reflecting its pricing power and cost economics. The operating margin of -4.14 and net profit margin of -2.26 provide insight into operational efficiency.

Gross Margin36.57
Operating Margin-4.14
Pretax Margin-0.15
Profit Margin-2.26
EBITDA Margin-1.26

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.31: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 1.69, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Navicare Biotech Co., Ltd. shareholders.

Shareholder Yield1.69
FCF Yield-1.31

Scores

As of June 30, 2026, Navicare Biotech Co., Ltd. has an Altman Z-Score of 1.39, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.39